CA3080900C - Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer - Google Patents
Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer Download PDFInfo
- Publication number
- CA3080900C CA3080900C CA3080900A CA3080900A CA3080900C CA 3080900 C CA3080900 C CA 3080900C CA 3080900 A CA3080900 A CA 3080900A CA 3080900 A CA3080900 A CA 3080900A CA 3080900 C CA3080900 C CA 3080900C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- imino
- ethoxy
- flt3
- dihydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0144142 | 2017-10-31 | ||
| KR20170144142 | 2017-10-31 | ||
| PCT/KR2018/013051 WO2019088677A1 (ko) | 2017-10-31 | 2018-10-30 | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3080900A1 CA3080900A1 (en) | 2019-05-09 |
| CA3080900C true CA3080900C (en) | 2022-10-25 |
Family
ID=66333236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3080900A Active CA3080900C (en) | 2017-10-31 | 2018-10-30 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11370779B2 (https=) |
| EP (1) | EP3705474A4 (https=) |
| JP (1) | JP7005779B2 (https=) |
| KR (1) | KR102247795B1 (https=) |
| CN (1) | CN111542513A (https=) |
| AU (1) | AU2018358582B2 (https=) |
| BR (1) | BR112020008499A2 (https=) |
| CA (1) | CA3080900C (https=) |
| MX (1) | MX2020004374A (https=) |
| PH (1) | PH12020550491A1 (https=) |
| RU (1) | RU2763346C2 (https=) |
| WO (1) | WO2019088677A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12433834B2 (en) | 2019-04-26 | 2025-10-07 | Conopco, Inc. | Hair conditioning composition |
| CN110305056A (zh) * | 2019-05-22 | 2019-10-08 | 西北大学 | 靛玉红新衍生物及其药用用途 |
| CN114521142B (zh) * | 2019-11-04 | 2024-07-02 | Ck雷容股份有限公司 | 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法 |
| KR102296440B1 (ko) * | 2019-12-06 | 2021-09-02 | 주식회사 펠레메드 | 신규한 인디루빈 유도체 및 이의 용도 |
| KR102443617B1 (ko) * | 2019-12-06 | 2022-09-16 | 광주과학기술원 | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 |
| KR102278176B1 (ko) | 2020-02-20 | 2021-07-16 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR20210106155A (ko) | 2020-02-20 | 2021-08-30 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR102325607B1 (ko) | 2020-02-20 | 2021-11-12 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| KR102744517B1 (ko) * | 2022-02-14 | 2024-12-19 | 주식회사 펠레메드 | 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도 |
| WO2024181799A1 (ko) * | 2023-02-28 | 2024-09-06 | 주식회사 씨케이리제온 | 신규한 인돌린 유도체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20010735A2 (en) * | 1999-04-12 | 2002-12-31 | Gerhard Eisenbrand | Indigoid bisindole derivatives |
| FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| KR100588803B1 (ko) | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| US8552053B2 (en) * | 2005-12-23 | 2013-10-08 | Centre National De La Recherche Scientifique | 7-substituted indirubin-3′oximes and their applications |
| EP2149553B1 (en) * | 2008-08-01 | 2011-10-19 | Centre National de la Recherche Scientifique | 3', 6-substituted indirubins and their biological applications |
| KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
| EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
| US10435367B2 (en) * | 2013-03-14 | 2019-10-08 | City Of Hope | Indirubin derivatives, and uses thereof |
| US20150087687A1 (en) * | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CA2902914A1 (en) * | 2013-03-14 | 2014-09-25 | City Of Hope | 5-bromo-indirubins |
| US20150259288A1 (en) * | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
-
2018
- 2018-10-30 CA CA3080900A patent/CA3080900C/en active Active
- 2018-10-30 RU RU2020115581A patent/RU2763346C2/ru active
- 2018-10-30 EP EP18873750.6A patent/EP3705474A4/en active Pending
- 2018-10-30 BR BR112020008499-9A patent/BR112020008499A2/pt not_active IP Right Cessation
- 2018-10-30 KR KR1020180131294A patent/KR102247795B1/ko active Active
- 2018-10-30 JP JP2020543443A patent/JP7005779B2/ja active Active
- 2018-10-30 CN CN201880084849.8A patent/CN111542513A/zh active Pending
- 2018-10-30 AU AU2018358582A patent/AU2018358582B2/en active Active
- 2018-10-30 MX MX2020004374A patent/MX2020004374A/es unknown
- 2018-10-30 WO PCT/KR2018/013051 patent/WO2019088677A1/ko not_active Ceased
-
2020
- 2020-04-24 PH PH12020550491A patent/PH12020550491A1/en unknown
- 2020-04-30 US US16/862,923 patent/US11370779B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200270229A1 (en) | 2020-08-27 |
| CA3080900A1 (en) | 2019-05-09 |
| RU2020115581A (ru) | 2021-12-02 |
| RU2020115581A3 (https=) | 2021-12-02 |
| JP7005779B2 (ja) | 2022-02-10 |
| WO2019088677A1 (ko) | 2019-05-09 |
| JP2021501208A (ja) | 2021-01-14 |
| RU2763346C2 (ru) | 2021-12-28 |
| AU2018358582B2 (en) | 2021-06-10 |
| AU2018358582A1 (en) | 2020-05-07 |
| KR20190049584A (ko) | 2019-05-09 |
| CN111542513A (zh) | 2020-08-14 |
| MX2020004374A (es) | 2020-11-11 |
| PH12020550491A1 (en) | 2021-01-11 |
| BR112020008499A2 (pt) | 2020-10-20 |
| EP3705474A1 (en) | 2020-09-09 |
| KR102247795B9 (ko) | 2023-04-12 |
| KR102247795B1 (ko) | 2021-05-04 |
| EP3705474A4 (en) | 2021-06-09 |
| US11370779B2 (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3080900C (en) | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | |
| AU2016276806B2 (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| JP2005511540A (ja) | インドリノン化合物を用いる急性骨髄性白血病の治療 | |
| TW200307535A (en) | Therapeutic agent for cancer | |
| WO2014165090A1 (en) | Compounds for the treatment of tuberculosis | |
| JP5820080B2 (ja) | 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤 | |
| EP3661935B1 (en) | Substituted pyrazolopyrimidines useful as kinases inhibitors | |
| US20250235426A1 (en) | Pharmaceutical Combination and Use Thereof | |
| JP2025503139A (ja) | 固形腫瘍の治療のためのユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤 | |
| JP2005526794A5 (ja) | ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用 | |
| EP3064582A1 (en) | RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN | |
| US10173995B2 (en) | Pyridine compounds used as PI3 kinase inhibitors | |
| KR20210047850A (ko) | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 | |
| JP2021527071A (ja) | Ｅｐａｃ阻害剤としてのチエノ［２，３−ｂ］ピリジン誘導体及びその医薬用途 | |
| US12162876B2 (en) | Indazole kinase inhibitor and use thereof | |
| KR102682516B1 (ko) | 퀴놀린 구조를 갖는 pan-kit 키나제 억제제 및 이의 용도 | |
| CN116685324A (zh) | 用于预防或治疗与ron突变相关的胰腺癌的药物组合物及其使用方法 | |
| KR101995533B1 (ko) | [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| CA3241699A1 (en) | Compounds for treatment of cancer | |
| WO2014139391A1 (en) | Substituted pyridine compounds as kinases inhibitors | |
| KR100714370B1 (ko) | 항종양 활성을 갖는〔1,2,4〕―트리아졸로〔4,3―ｃ〕퀴나졸린 유도체 | |
| KR20210060461A (ko) | 피롤 치환된 인돌리논계 유도체 또는 이의 약학적으로 허용 가능한 염, 및 이의 제조 방법 및 이의 용도 | |
| HK1224702A1 (en) | Resistant mutant 90 kda heat shock protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200429 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241001 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241001 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |